Form 4: Aclaris CBO Loerop Reports RSU Vesting, Tax Withholding

Aclaris Therapeutics' Chief Business Officer, James Loerop, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations.

Summary

• James Loerop, Chief Business Officer of Aclaris Therapeutics, Inc. (ACRS), reported transactions involving the company's common stock.
• On December 31, 2025, Loerop acquired 73,750 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently on December 31, 2025, 33,994 shares were disposed of at $3.01 per share to satisfy tax withholding obligations related to the RSU vesting.
• On January 2, 2026, an additional 18,150 shares were acquired from RSU vesting.
• On the same date, January 2, 2026, 6,171 shares were disposed of at $2.88 per share for tax withholding purposes.
• Following these transactions, Loerop beneficially owns 155,041 shares of common stock directly.
• The RSUs vesting on December 31, 2025, were part of an award where 50% vested on December 31, 2024, and the remaining 50% on December 31, 2025.
• The RSUs vesting on January 2, 2026, are part of an award that vests 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to continuous service.

Sentiment

Score: 5

Explanation: The filing details routine, pre-scheduled insider transactions related to executive compensation (RSU vesting and tax withholding). These events are neutral in sentiment as they do not indicate new strategic developments, operational performance changes, or unexpected insider behavior.

Positives

• The vesting of restricted stock units indicates continued executive compensation and retention of a key officer.
• The acquisition of shares through RSU vesting increases the Chief Business Officer's direct ownership in the company, aligning his interests with shareholders.

Negatives

• A portion of the vested shares was sold to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

The remaining portion of the restricted stock units that partially vested on January 2, 2026, is scheduled to vest 34% on January 2, 2027, contingent on the Chief Business Officer's continuous service.

Industry Context

This filing represents a routine insider transaction related to executive compensation in the biotechnology and pharmaceutical industry. Equity-based compensation, such as restricted stock units, is a common practice to incentivize and retain key management personnel, aligning their long-term interests with company performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of executive compensation is a standard practice across publicly traded companies, particularly in the biotech sector, comparable to compensation structures at companies like Regeneron Pharmaceuticals or Biogen.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is also a common and expected event, often executed through a Rule 10b5-1 plan, which is a standard mechanism for insiders to trade company stock without concerns of insider trading.

Stakeholder Impact

• Shareholders: Minor impact, as these are routine compensation-related transactions and do not signal a change in company fundamentals or strategy.
• Employees: Reinforces the company's compensation structure for executives, potentially impacting morale or expectations regarding equity awards.
• Management: The Chief Business Officer's compensation package is being realized, aligning his financial interests with the company's stock performance.

Next Steps

• The remaining 34% of certain restricted stock units are scheduled to vest on January 2, 2027, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing reports routine, pre-scheduled insider transactions related to executive compensation (vesting of restricted stock units and subsequent share dispositions for tax withholding). It does not contain any new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing provides no new fundamental catalysts for a 'buy' or 'sell' decision.

Keywords

Aclaris Therapeutics, ACRS, James Loerop, Chief Business Officer, Restricted Stock Units, RSU vesting, Insider Transaction, Form 4, Equity Compensation, Tax Withholding